Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03015740 · ClinicalTrials.gov registry record · Phase 1
Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney Cancer
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT03015740: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT03015740 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 42 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03015740, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
This phase I/II trial studies the side effects of sitravatinib and how well it works with nivolumab in treating patients with kidney cancer that has spread to other places in the body. Sitravatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving sitravatinib and nivolumab may work better in treating patients with kidney cancer.
Interventions
- OTHER Quality-of-Life Assessment
- OTHER Laboratory Biomarker Analysis
- OTHER Questionnaire Administration
- BIOLOGICAL Nivolumab
- DRUG Sitravatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2017-04-23 |
| Est. Completion | 2022-09-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03015740
The ClinicalTrials.gov registry entry for NCT03015740 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Quality-of-Life Assessment is the first listed.
NCT03015740 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03015740 about?
NCT03015740 is a clinical study titled "Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney Cancer". This phase I/II trial studies the side effects of sitravatinib and how well it works with nivolumab in treating patients with kidney cancer that has spread to other places in the body. Sitravatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunothera...
What is the current status of trial NCT03015740?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2017-04-23. Estimated completion is 2022-09-06.
What interventions are being tested in trial NCT03015740?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Laboratory Biomarker Analysis (OTHER), Questionnaire Administration (OTHER), Nivolumab (BIOLOGICAL), Sitravatinib (DRUG).
Who is sponsoring clinical trial NCT03015740?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.